Short Interest in Tema Oncology ETF (NASDAQ:CANC) Rises By 283.3%

Tema Oncology ETF (NASDAQ:CANC) was the target of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 2,300 shares, an increase of 283.3% from the September 15th total of 600 shares. Based on an average daily trading volume, of 5,000 shares, the short-interest ratio is currently 0.5 days.

Institutional Investors Weigh In On Tema Oncology ETF

An institutional investor recently bought a new position in Tema Oncology ETF stock. Thrivent Financial for Lutherans acquired a new position in Tema Oncology ETF (NASDAQ:CANC) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 319,376 shares of the company’s stock, valued at approximately $8,616,000. Thrivent Financial for Lutherans owned about 19.01% of Tema Oncology ETF as of its most recent SEC filing.

Tema Oncology ETF Stock Up 2.2 %

Shares of CANC stock traded up $0.60 during mid-day trading on Friday, reaching $28.48. The stock had a trading volume of 3,074 shares, compared to its average volume of 7,297. The firm’s 50 day simple moving average is $28.70 and its 200 day simple moving average is $27.88. The firm has a market cap of $49.56 million, a PE ratio of 26.86 and a beta of 1.11. Tema Oncology ETF has a one year low of $21.26 and a one year high of $30.11.

Tema Oncology ETF Company Profile

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.